Crinetics: A Biotech Gamble with a $290K Price Tag

Let’s talk numbers. If Crinetics captures half the market – ambitious, sure – that’s 5,500 patients generating $800 million in net revenue after discounts. Goldman Sachs, ever the pessimist, values the company at 7 times its $600 million peak sales estimate. Others imagine $1.5 billion in sales and multiples closer to 3. The gap between these outcomes is vast. Investors could double their money or lose half. So it goes.








